Biotech venture capital off to a $659m start in 2015
This article was originally published in Scrip
Just six days into 2015, the US biotechnology industry already is halfway to the $1.1bn in venture capital raised during the first three months of 2014, including a $48m Series B round for Global Blood Therapeutics (GBT), a $65m Series D for Seres Health and a $20m Series C for CytomX.
You may also be interested in...
J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.
Women fill many roles in biopharma companies, but relatively few are in leadership positions. Executives who spoke with Scrip in a roundtable discussion during the J.P. Morgan Healthcare Conference earlier this month noted the disconnect, but saw some hope for improved gender diversity in the future.